articleThe Lancet OncologyNov 12, 2009Closed access

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

University of Alabama at Birmingham · University of Alabama at Birmingham Hospital · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,971
total citations
FWCI
96.97
Percentile
100%
References
49
Citations per year

Authors

13

Topics & keywords

Keywords
  • Medicine
  • Cetuximab
  • Head and neck cancer
  • Clinical endpoint
  • Radiation therapy
  • Rash
  • Internal medicine
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.